Lexaria Bioscience Corp. filed a Form D with the Securities and Exchange Commission on 2025-12-19.
Lexaria Bioscience Corp. filed a Form D notice of an exempt securities offering with the SEC on December 19, 2025. The filing reports $3.50M sold. Its industry group is Biotechnology. It names Christopher Bunka (Director), John Docherty (Executive Officer, Director), Richard Christopher (Executive Officer, Director) (SEC Form D, December 19, 2025).
Sell to companies like Lexaria Bioscience Corp? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-12-19 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Lexaria Bioscience Corp.
Free to see. No signup.
More on the people and the money behind Lexaria Bioscience Corp., from the filings we hold.
H.C. WAINWRIGHT & CO. received sales compensation on this raise and on 12 other raises we hold, nearest in date first:
Biotechnology raises filed within 90 days of this one, largest first.
Get an email when Lexaria Bioscience Corp. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Lexaria Bioscience Corp. raises, hires or launches. No email unless you switch it on.
Watch Lexaria Bioscience Corp. →Get the full cited report on Lexaria Bioscience Corp.
What the filing shows about Lexaria Bioscience Corp.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Lexaria Bioscience Corp.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for Lexaria Bioscience Corp. →
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Lexaria Bioscience Corp. See pricing
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 759 filings in Biotechnology, totalled by week. The dot is this raise, $3.50M, on the same scale — one filing against the whole group's total, so it sits low by construction.
Christopher Bunka is named as Director on the Form D that Lexaria Bioscience Corp. filed with the SEC on 19 December 2025, one of 8 people that filing names.
John Docherty is named as Executive Officer and Director on the Form D that Lexaria Bioscience Corp. filed with the SEC on 19 December 2025, one of 8 people that filing names.
Richard Christopher is named as Executive Officer and Director on the Form D that Lexaria Bioscience Corp. filed with the SEC on 19 December 2025, one of 8 people that filing names.
Michael Shankman is named as Executive Officer on the Form D that Lexaria Bioscience Corp. filed with the SEC on 19 December 2025, one of 8 people that filing names.
Nicholas Baxter is named as Director on the Form D that Lexaria Bioscience Corp. filed with the SEC on 19 December 2025, one of 8 people that filing names.
William McKechnie is named as Director on the Form D that Lexaria Bioscience Corp. filed with the SEC on 19 December 2025, one of 8 people that filing names.
Albert Reese is named as Director on the Form D that Lexaria Bioscience Corp. filed with the SEC on 19 December 2025, one of 8 people that filing names.
Bal Bhullar is named as Director on the Form D that Lexaria Bioscience Corp. filed with the SEC on 19 December 2025, one of 8 people that filing names.
8 people named on the filing — 3 holding an executive role and 5 as directors only.
Named as of the 2025-12-19 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Lexaria Bioscience Corp.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Lexaria Bioscience Corp.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Lexaria Bioscience Corp. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Lexaria Bioscience Corp.You get an alert in MentionFox the next time this company shows up.
If you're behind Lexaria Bioscience Corp.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Lexaria Bioscience Corp.. With no account yet, you sign up free and land on the result.
https://mentionfox.com/funding/lexaria-bioscience-corp-form-d-25000001